Tse-I Lin, D.Phil., currently holds the position of Vice President, Early Compound Development and site head of Leuven in Belgium at Aligos Therapeutics. He started his professional life as Post-Doc at Bayer Pharmaceutical in Germany. He subsequently joined JNJ/Tibotec BVBA in 2003 and worked for over 12 years at Janssen Pharmaceutical in antiviral drug discovery and development, focusing on HBV and HCV, including the HCV protease inhibitor, Simeprevir, which was launched in the US in 2013. In 2010, he took a leadership position in Shanghai for JNJ where he built an antiviral R&D group. In 2013 Tse-I joined Roche as the Head of Molecular Virology Group to lead discovery groups both in Shanghai and Basel, Switzerland. In 2015 He became the Leader of the China Acceleration Strategy for the Roche Infectious Disease group. In 2016 he joined Janssen’s infectious disease group and continued to work on HBV, as the early development project leader. Dr. Lin obtained his B.S. in Public Health from National Taiwan University, Masters and Ph.D. in Biochemistry from Freie Berlin University in Germany.
